Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2024 · 10-Q
Revenue$22.30M$22.30M+11.6% vs Q2 2023 Net Income-$52.99M-$52.99MN/M vs Q2 2023 EPS Diluted-$1.05-$1.05N/M vs Q2 2023 Operating Income-$56,037,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$45,971,000N/M Margins · derivedOperating margin-251.3%+114.6 pt vs Q2 2023
Net margin-237.7%+123.0 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 1, 2024 · 32 d after period end